Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Amphetamine

or Analgesic

or Antidepressant

Use the filters below to narrow your results.

Codeine (2)

None (12) · (multiple, generic dominant) (1) · Adderall, Adderall XR, Mydayis (1) · Anafranil (1) · Aurorix (1) · Captagon (1) · Cymbalta, Drizalma Sprinkle, Irenka, Yentreve (1) · Darvon (1) · Demerol (1) · Desoxyn (1) · Dexedrine (1) · Dilaudid (1) · Dolophine (1) · Duragesic (1) · Edronax (1) · Fetzima (1) · Ludiomil (1) · Marplan (1) · Nardil (1) · Norpramin (1) · Nubain (1) · Nucynta (1) · Opana (1) · Parnate (1) · Savella (1) · Serzone (1) · Stablon (1) · Stadol (1) · Suboxone (1) · Surmontil (1) · Talwin (1) · Tofranil (1) · Valdoxan (1) · Vicodin (1) · Vivactil (1) · Zoloft (1)

Irreversible non-selective MAO inhibitor (3) · Kappa agonist; mu antagonist (1) · Kappa agonist; mu partial agonist (1) · Kappa agonist; mu partial agonist/antagonist (1) · Melatonin receptor agonist; 5-HT2C antagonist (1) · Monoamine releasing agent (6) · Monoamine releasing agent, TAAR1 agonism, VMAT2 substrate, DAT/NET reverse transport (1) · Monoamine releasing agent; serotonergic at higher doses (1) · Mu-opioid agonist; modulates glutamate AMPA receptors (1) · Mu-opioid agonist; norepinephrine reuptake inhibitor (1) · Mu-opioid receptor agonist (4) · Mu-opioid receptor agonist; NMDA antagonist (1) · Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · Mu-opioid receptor agonist; sodium channel blocker (1) · Mu/kappa/delta agonist; NMDA antagonist (1) · Partial mu-opioid agonist; kappa antagonist (1) · Phosphodiesterase inhibitor; calcium channel blocker (1) · Potent mu-opioid receptor agonist (3) · Potent serotonin reuptake inhibitor; also NRI (1) · Prodrug of amphetamine + theophylline (1) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) · Reversible inhibitor of MAO-A (1) · Selective norepinephrine reuptake inhibitor (3) · Serotonin and norepinephrine reuptake inhibitor (3) · Serotonin reuptake inhibitor and 5-HT2A antagonist (1) · Serotonin–norepinephrine reuptake inhibition (balanced) (1) · Serotonin–norepinephrine reuptake inhibitor (2) · TAAR1 agonism, VMAT2 substrate, DAT/NET reverse transport, net release of dopamine and norepinephrine (1) · TrkB/BDNF'"`UNIQ--ref-00000084-QINU`"' '"`UNIQ--vote-00000085-QINU`"' (1) · Weak SRI; primarily H1/D2/alpha antagonist (1)

None (43) · Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) · Mild to moderate pain; cough suppression (low-dose). (1) · '"`UNIQ--vote-000004B9-QINU`"', '"`UNIQ--vote-000004BA-QINU`"', '"`UNIQ--vote-000004BB-QINU`"' (1) · '"`UNIQ--vote-00000562-QINU`"', '"`UNIQ--vote-00000563-QINU`"', '"`UNIQ--vote-00000564-QINU`"', '"`UNIQ--vote-00000565-QINU`"', '"`UNIQ--vote-00000566-QINU`"' (1)

None (43) · 2.5 mg IR, 5 mg XR, or 12.5mg Mydayis (1) · 25 mg (1) · 5 mg PO (1) · Adult: 15–60 mg every 4 hours as needed. (1)

None (43) · 25 mg, 50 mg, 100 mg tablets; oral concentrate 20 mg/mL (1) · Desoxyn 5 mg tabs (1) · IR tabs 5, 7.5, 10, 12.5, 15, 20, 30 mg; XR caps 5, 10, 15, 20, 25, 30 mg; Mydayis caps 12.5, 25, 37.5, 50 mg (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (43) · 200 mg/d (1) · 25 mg/day (ADHD per Desoxyn label); 15 mg/day (obesity, short-term, per Desoxyn label) (1) · 360 mg/day (1) · XR = 40 or 60 mg/d; IR = 40 or 60 mg/d'"`UNIQ--ref-00000567-QINU`"' (1)

None (42) · Oral (3) · Oral (prescribed) (1) · PO (only formulation marketed in the US). (1)

None (43) · 30–60 min (PO) (1) · Anxiolysis classically 3-4 weeks, continuing improvement to 8-12 weeks (1) · IR: 30–60 min; XR: 1–2 h to peak effect (1) · Mood: 2–4 weeks. Pain: often within 1–2 weeks. (1)

None (43) · 4–6 hours (1) · Chronic daily dosing (1) · IR 4–6 h; XR 10–12 h; Mydayis 14–16 h (1) · Long (1)

None (43) · 2.5–3 hours (1) · D-amphetamine ~10 h; L-amphetamine ~13 h (adults) (1) · ~12 hours (1) · ~26 h (sertraline; range 13-45 h, longer in females); ~62-104 h (N-desmethylsertraline, weakly active) (1)

None (43) · Absolute bioavailability not precisely characterized; food modestly increases exposure (1) · ~50% (highly variable) (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1) · ~75–90% (oral) (1)

None (42) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Category C (2) · Category C (per Desoxyn label) (1) · Category C'"`UNIQ--ref-0000008F-QINU`"' (1)

None (42) · Rx-only (1) · Rx-only in US (1) · Schedule II (2) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1)